Michael P. Dube Sells 2,012 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the transaction, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at $893,698.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA opened at $17.99 on Friday. Intellia Therapeutics, Inc. has a 52 week low of $17.43 and a 52 week high of $34.87. The company has a market cap of $1.74 billion, a PE ratio of -3.36 and a beta of 1.76. The firm has a 50 day simple moving average of $22.00 and a 200 day simple moving average of $23.51.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The business had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $19.68 million. The firm’s revenue was down 48.5% on a year-over-year basis. During the same period in the previous year, the business earned ($1.40) EPS. On average, equities analysts predict that Intellia Therapeutics, Inc. will post -5.22 earnings per share for the current year.

Institutional Trading of Intellia Therapeutics

Several hedge funds have recently modified their holdings of NTLA. First Horizon Advisors Inc. grew its position in Intellia Therapeutics by 22.1% during the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after buying an additional 472 shares in the last quarter. Interchange Capital Partners LLC grew its position in Intellia Therapeutics by 6.5% in the 1st quarter. Interchange Capital Partners LLC now owns 10,909 shares of the company’s stock valued at $303,000 after purchasing an additional 670 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in Intellia Therapeutics by 9.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,894 shares of the company’s stock valued at $245,000 after acquiring an additional 750 shares in the last quarter. Axxcess Wealth Management LLC raised its stake in shares of Intellia Therapeutics by 6.5% during the 1st quarter. Axxcess Wealth Management LLC now owns 16,602 shares of the company’s stock worth $457,000 after purchasing an additional 1,010 shares during the period. Finally, Intellectus Partners LLC lifted its stake in shares of Intellia Therapeutics by 2.1% during the 2nd quarter. Intellectus Partners LLC now owns 58,225 shares of the company’s stock valued at $1,303,000 after buying an additional 1,225 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NTLA. Royal Bank of Canada reiterated an “outperform” rating and issued a $54.00 price target on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Evercore ISI raised shares of Intellia Therapeutics to a “strong-buy” rating in a research note on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 24th. JPMorgan Chase & Co. reduced their target price on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Finally, StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research report on Thursday, June 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.77.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.